முதலீட்டாளர் விளக்கக்காட்சி
டீல்
டீல் மதிப்பு—
டீல் vs வணிகம்UK acquisition adds ~GBP 65M/qtr (~₹2,600 Cr/yr) relative to ₹7,896 Cr TTM revenue (~33% revenue step-up) plus 5.3% bed capacity addition (total 6,269 beds)
செயல்படுத்தும் காலம்3.0 ஆண்டு
அடிப்படை தரம்B
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)34.0% / 48.0%
EPS உயர்வு30.0%
அப்சைடு பேஸ் / புல் / பேர்35.0% / 65.0% / -20.0%
கால எல்லை24-36 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம்(04 ஆக. 2026)₹1919.7
சமீபத்திய முடிவு விலை(12 நவ. 2026)₹1840.1
தொடங்கியதிலிருந்து வருமானம்-4.1%
α vs Smallcap 250-3.4%
α vs சொந்தத் துறை+1.5% (ஹெல்த்கேர் இடைநிலை -4.9%, 55 முதிர்ந்த தேர்வுகளின் அடிப்படையில்)
நேர்மறைகள்
- Substantial scale expansion with Q1 FY27 revenue surging 78% YoY to ₹2,683.6 Cr, driven by the full consolidation of UK operations.
- Strong India hospital core metrics with ARPOB increasing to ₹19.2 Mn (vs ₹17.6 Mn in Q1 FY26) reflecting high-complexity surgical mix.
- Healthy underlying profitability with ROCE at 20.0% and strong cash flow generation from mature Indian flagship units.
- Strategic multi-engine growth pipeline involving ₹3,000 Cr planned capex across greenfield/brownfield projects in Kolkata, Bengaluru, and Cayman Islands.
அபாயங்கள்
- Margin dilution from initial integration of UK operations, driving consolidated EBITDA margin down to 18.8% compared to 24.8% in core India hospitals.
- Gestation losses in nascent health insurance (NHIC) business, incurring a PAT loss of ₹20.1 Cr in Q1 FY27 with potential risk of loss-ratio volatility.
- Increased leverage with Net Debt standing at ₹1,967 Cr following international acquisitions and aggressive capex commitments.
நிர்வாக எச்சரிக்கைகள்
- Audit dependency noted for seven subsidiaries representing assets of ₹1,248.88 Million audited by non-parent audit firms.
முழு AI சுருக்கம்
Narayana Hrudayalaya (NH) - PIT Equity Research Analysis
1. Industry Context & Quality Gate
- Industry Structure: Private healthcare providers operate in a capital-intensive environment with multi-year payback periods (3-5 years to break even on greenfield hospitals). Private healthcare in India grows at a structural CAGR of 12-14% due to under-penetration and rising insurance coverage.
- Quality Metrics: ROCE stands at 20.0%, passing the quality gate. D/E ratio is 0.76 with ₹1,970 Cr debt supporting heavy inorganic and organic capex. Promoter holding is stable at 63.3%.
2. Ramp-Aware Catalyst Impact Math
- Event Context: The presentation details Q1 FY27 performance where consolidated revenue grew 78% YoY to ₹2,683.6 Cr. This is driven primarily by the consolidation of the UK acquisition (GBP 65.0M revenue in Q1) and ongoing domestic expansion (+5.3% bed capacity to 6,269 beds).
- Already Priced In: YES. The exact revenue (₹2,684 Cr) and UK consolidation details were disclosed 3 days prior on July 31, 2026 in the Q1 FY27 earnings release.
- Revenue Impact: TTM revenue of ₹7,896 Cr will step up to ~₹10,500-11,000 Cr in Year 1 (~34% annual uplift) as UK operations are fully consolidated. Over a 3-year steady-state horizon, capacity additions in Bengaluru, Kolkata, and Cayman will lift annual revenues by ~48%.
- Earnings Impact: Consolidated EBITDA margins fell from historical ~22-23% to 18.8% due to lower-margin UK assets and ₹20.1 Cr Q1 gestation loss in insurance (NHIC). Assuming UK margins ramp up and insurance losses cap out, steady-state EPS can grow ~30% over 24-36 months.
3. மதிப்பீடு & சூழல் அளவுத்திருத்தம்
- Valuation: Trading at 48.6x trailing P/E against a peer median of 69.5x (e.g., Apollo, Fortis, KIMS). While not cheap, it trades at a discount to peers despite superior ROCE.
- Base Case (+35%): UK margins improve to ~20%, India hospitals maintain 24%+ EBITDA margins, and insurance losses narrow. Market cap expands toward ₹52,900 Cr.
- Bull Case (+65%): Fast UK margin turn-around to 22%, rapid bed fill in Cayman Bay & India greenfields, and insurance arm achieving operational breakeven early.
- Bear Case (-20%): Prolonged margin drag from UK acquisitions, escalating insurance underwriting losses, and regulatory pricing caps on procedures in India.
4. தீர்ப்பின் காரணம்
NH is a high-quality healthcare compounder with strong ROCE (20%). The 78% revenue jump marks a major scale transition, but near-term margin compression and gestation drag in insurance/UK cap near-term re-rating. Given that this catalyst was formally released 3 days prior, it is largely priced in near-term, yielding a POSSIBLE multibagger verdict over a 3-year horizon.
2026-08-03 நிலவரப்படி பகுப்பாய்வு (விலை ₹1925.00) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
